Results 121 to 130 of about 952,825 (268)
Addressing Economic Insecurities Can Improve Patient‐Reported Outcomes in Lupus
Arthritis Care &Research, EarlyView.Objective Economic insecurities, such as food, housing, transportation, and financial challenges, are modifiable risk factors and influence patient‐reported outcomes (PROs) in systemic lupus erythematosus (SLE). We examined the following: (1) associations between economic insecurities and PROs, and (2) the impact of screening and addressing economic ...
Jay Patel +8 more
wiley +1 more source
Arthritis Care &Research, EarlyView.Objective Frailty occurs prematurely in rheumatoid arthritis (RA) and is associated with poor health outcomes. We compared the performance of four frailty instruments, including a pragmatic alternative measure using chair sit‐to‐stand (STS), and evaluated their abilities to predict poor health outcomes.
Kylie E. Riggles +14 more
wiley +1 more source
Rheumatologic Manifestations of Patients With Type B Insulin Resistance
Arthritis Care &Research, EarlyView.Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya +4 more
wiley +1 more source
Arthritis Care &Research, EarlyView.Objective We aimed to estimate the prevalence and cumulative incidence of hydroxychloroquine retinopathy (HCQ‐R) and its risk factors among patients receiving long‐term HCQ with rheumatic diseases through a systematic review and meta‐analysis of observational studies that used spectral‐domain optical coherence tomography (SD‐OCT) for screening ...
Narsis Daftarian +4 more
wiley +1 more source
Arthritis Care &Research, EarlyView.Objective Clinical response to mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug level monitoring (TDM) may help improve treatment efficacy. This systematic review and meta‐analysis examined therapeutic ranges for MPA levels associated with better outcomes and safety in patients with systemic lupus erythematosus (SLE ...
Zahraa Qamhieh +5 more
wiley +1 more source
Feline comorbidities: cardiovascular and kidney diseases. [PDF]
J Feline Med SurgColeman AE, Lourenço BN.
europepmc +1 more source
Arthritis Care &Research, EarlyView.Objective Despite well‐described biologic causes, the public views unhealthy lifestyle choices as the primary cause of gout. This study investigated how causal beliefs about gout influence the public's views about its management. Methods In a randomized study, 201 members of the public viewed one of two 2‐minute videos about gout.
Rachel Murdoch +6 more
wiley +1 more source
A new perspective on the pathophysiology of kidney diseases: the intracellular complement system- "complosome". [PDF]
Front NephrolLeventoğlu E, Bakkaloğlu SA.
europepmc +1 more source
Arthritis Care &Research, EarlyView.Objective Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), but the weight‐based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to identify clinical factors that predict ...
Jay J. Patel +6 more
wiley +1 more source
Genetic kidney diseases - from discovery to precision care. [PDF]
Med GenetSimons M, Hoefele J.
europepmc +1 more source